Blog
📢 Moleac Announces PT Ferron Par Pharmaceuticals as New Exclusive Partner in Indonesia
Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as PT Ferron Par Pharmaceuticals will become our exclusive partner in Indonesia effective Jan 1ˢᵗ 2025.
Join Us at the World Stroke Congress 2024 in Abu Dhabi – Visit Us at Booth 14!
We are thrilled to announce our participation at the World Stroke Congress (WSC) from October 23ʳᵈ to 26ᵗʰ, 2024, in Abu Dhabi.
Clinical Meaningfulness in Alzheimer’s Disease Trials: Key Insights from the EU-US CTAD Task Force Report
In their study, Angioni et al. report several general principles identified by the EU-US CTAD Task Force that should be considered when evaluating the meaningfulness of clinical trial results.